Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine by Claire I. Daïen, Jacques Morel

“…Genetic background, cytokine levels, and immune cell phenotypes could also influence biological therapy response. This review summarizes the impact of all those parameters on response to biological therapies.…”
Get full text

Increasing the concentration of plasma molecules improves the biological activity of platelet-rich plasma for tissue regeneration by Mikel Sánchez, Jon Mercader Ruiz, Daniel Marijuán Pinel, Pello Sánchez, Nicolás Fiz, Jorge Guadilla, Juan Azofra, Maider Beitia, Diego Delgado

Get full text

Surgical treatment of the fistulizing Crohn's disease with anterior abdominal wall reconstruction (Clinical case) by Yu. Ye. Kitsenko, O. S. Shifrin, P. V. Tsarkov

“…At continuation of biological therapy by adalimumab no data on disease relapse were received. …”
Get full text

T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy by Sonja Dulic, Zsófia Vásárhelyi, Florentina Sava, László Berta, Balázs Szalay, Gergely Toldi, László Kovács, Attila Balog

“…Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limited. …”
Get full text

Common Adverse Effects of Anti-TNF Agents on Gestation by Zacharias Fasoulakis, Panagiotis Antsaklis, Nikolaos Galanopoulos, Emmanuel Kontomanolis

“…However a lot of women will require continuation of disease-modifying therapies (i.e., biological therapies) throughout pregnancy and post-partum involving many risks. …”
Get full text

Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments by Bruno Rafael Ramos de Mattos, Maellin Pereira Gracindo Garcia, Julia Bier Nogueira, Lisiery Negrini Paiatto, Cassia Galdino Albuquerque, Caique Lopes Souza, Luís Gustavo Romani Fernandes, Wirla Maria da Silva Cunha Tamashiro, Patricia Ucelli Simioni

“…Nowadays, advances in treatments for IBD have included biological therapies, based mainly on monoclonal antibodies or fusion proteins, such as anti-TNF drugs. …”
Get full text

Biologic Agents in Crohn’s Patients Reduce CD4+ T Cells Activation and Are Inversely Related to Treg Cells by Eliane Aparecida Rosseto-Welter, Leticia D’argenio-Garcia, Filipa Blasco Tavares Pereira Lopes, Ana Eduarda Zulim Carvalho, Fernando Flaquer, Vanessa Severo-Lemos, Claudia Concer Viero Nora, Flavio Steinwurz, Lucas Pires Garcia Oliveria, Thiago Aloia, Luiz Vicente Rizzo, Cristóvão Luis Pitangueira Mangueira, Karina Inacio Carvalho

“…There are two main treatments for Chron’s disease: biological therapy and nonbiological therapy. Biological agent therapy (e.g., anti-TNF) is the most frequently prescribed treatment; however, it is not universally accessible. …”
Get full text

Connections and Unmet Needs: Severe Asthma Biologics and Osteoporosis by Fabiana Furci, Marco Umberto Scaramozzino, Giuseppe Rocco Talesa, Corrado Pelaia

“…With the use of new, available biologic therapies for asthma, perhaps even anticipating the times of their use in therapeutic management, in the current guidelines and with targeted strategies of prevention it may be possible to improve asthma management, preventing some comorbidities, such as osteoporosis.…”
Get full text

Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy by A. I. Khavkin, A. V. Nalyotov, N. A. Marchenko

“…At the same time, strategies for diagnosing and treating these patients are being improved: doctors began using high-definition endoscopy and video capsule endoscopy, the determination of fecal calprotectin, biological therapy (infliximab, adalimumab, vedolizumab, and ustekinumab) and drug monitoring. …”
Get full text

Relapsing Polychondritis in a Patient with Ankylosing Spondylitis Using Etanercept by Valderilio Feijó Azevedo, Natalia Bassalobre Galli, Alais Daiane Fadini Kleinfelder, Julia Farabolini D’Ippolito, Andressa Gulin Tolentino, Eduardo Paiva

“…The treatment was based on data in the literature and included the cessation of biological therapy and the addition of corticosteroids with substantial improvement.…”
Get full text

Clinical Perspectives - Biologics in IBD: What's All the Fuss? by Hillary Steinhart

“…This article examines the evidence behind the use of biologic therapies such as anti-tumour necrosis factor-alpha, interleukin-10, interleukin-11, anti-integrin antibody and antisense intercellular adhesion molecule-1 oligonucleotide.…”
Get full text

Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease by Tejas Sheth, C. S. Pitchumoni, Kiron M. Das

“…On the other hand, axial involvement is linked to gut inflammatory activity; hence, there is a considerable amount of treatment overlap. Biological therapies have revolutionized management of inflammatory bowel diseases as well as of associated articular manifestations. …”
Get full text

Tissue Engineered Strategies for Skeletal Muscle Injury by Umile Giuseppe Longo, Mattia Loppini, Alessandra Berton, Filippo Spiezia, Nicola Maffulli, Vincenzo Denaro

“…However, current management of muscle injuries often does not provide optimal restoration to preinjury status. New biological therapies, such as injection of platelet-rich plasma and stem-cell-based therapy, are appealing. …”
Get full text

Fecal Microbiota Transplantation: A New Therapeutic Attempt from the Gut to the Brain by Hao-Ming Xu, Hong-Li Huang, You-Lian Zhou, Hai-Lan Zhao, Jing Xu, Di-Wen Shou, Yan-Di Liu, Yong-Jian Zhou, Yu-Qiang Nie

“…Fecal microbiota transplantation (FMT) is a biological therapy that entails transferring the gut microbiota from healthy individuals to patients in order to reconstruct the intestinal microflora in the latter. …”
Get full text

Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal by Anita Annaházi, Tamás Molnár

“…This review summarizes the current knowledge on these topics with respect to 5-aminosalicylates, thiopurines, methotrexate, and biological therapies and collects information regarding when and in which specific patient groups, in the absence of risk factors, can withdrawal of therapy be considered without a high risk of relapse. …”
Get full text

Pouchitis unveiled: exploring clinical features, diagnosis, and cutting-edge treatments by Francesca Lusetti, Camilla Almeida Martins Helfenberger, Munique Kurtz de Mello, Natália Sousa Freitas Queiroz

“…Currently, there is still no consensus on the optimal management for CP, though recent progress in understanding the pathophysiology of pouchitis has paved the way for innovative therapeutic approaches, based on biological therapies and small molecules. This review aims to discuss the recent advanced therapies available for pouchitis and provide a comprehensive review on the topic to guide physicians in their clinical practice.…”
Get full text

Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy by Nwe Ni Than, Hannah C. Jeffery, Ye H. Oo

“…Standard treatment regimens involving steroid and immunosuppressive medications lead to global immune suppression requiring life-long therapy with many side effects. Biologic therapies have been attempted but duration of remission is short-lived. …”
Get full text

Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus by Ignacio Marin-Jimenez, Guillermo Bastida, Daniel Carpio, Fernando Muñoz, Yago González-Lama, Elena Ricart, Daniel Ceballos, Daniel Ginard, Luis Menchen

“…These statements cover: (1) use of first-line non-anti-TNF biological therapy; (2) role of HLA-DQA1*05 in daily practice; (3) attitudes in primary non-response and loss of response to anti-TNF therapy due to immunogenicity; (4) use of ustekinumab or vedolizumab if a change in action mechanism is warranted; (5) anti-TNF drug level monitoring; (6) combined therapy with an immunomodulator.Conclusion This document sought to pull together the best evidence, experts’ opinions, and treating physicians’ attitudes when using anti-TNF therapies in patients with CD.…”
Get full text

Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis by Isabelle Duroux-Richard, Yves-Marie Pers, Sylvie Fabre, Meryem Ammari, Dominique Baeten, Guillaume Cartron, Isabelle Touitou, Christian Jorgensen, Florence Apparailly

“…Although biologic therapies have changed the course of rheumatoid arthritis (RA), today’s major challenge remains to identify biomarkers to target treatments to selected patient groups. …”
Get full text

Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity by Ying-Chou Chen, Chi-Hua Ko, Jia-Feng Chen, Chung-Yuan Hsu, Wen-Chan Chiu, Tien-Tsai Cheng

“…The time needed for synovial hypertrophy to decrease may be up to 3–6 months after adalimumab therapy. Switching to biological therapy before 3–6 months is inappropriate and ineffective.…”
Get full text